Figure 2: Maximal oxygen consumption (VO2max) evaluated 2 and 31 days after pHuVEGF165 or saline intramyocardial injection in control (C), myocardial infarction + saline (I+SAL), myocardial infarction + VEGF (I+VEGF), diabetes + myocardial infarction + saline (DI+SAL), and diabetes + myocardial infarction + VEGF (DI+VEGF) groups. # p<0.05 vs. initial evaluation; * p<0.05 vs. C; † p<0.05 vs. I+SAL; ‡ p<0.05 vs. DI+SAL; (n=8 for each group).